DISTRIBUTION AGREEMENTDistribution Agreement • February 27th, 2018 • Amarin Corp Plc\uk • Pharmaceutical preparations • London
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.
DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENTDevelopment, Commercialization and Supply Agreement • February 27th, 2018 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This Development, Commercialization and Supply Agreement (this “Agreement”) is entered into as of the 25th day of September, 2017 (the “Effective Date”) by and among Amarin Pharmaceuticals Ireland Limited, a company incorporated under the laws of Ireland (registered number 408912) with offices at 2 Pembroke House Upper Pembroke Street 28-32, Dublin 2, Ireland (“Amarin Ireland”), and Amarin Pharma, Inc., a Delaware corporation with offices at 1430 Route 206 North, Suite 200, Bedminster, NJ 07921 (“Amarin Pharma”, and collectively with Amarin Ireland, “Amarin”), on the one hand, and HLS Therapeutics Inc., located at 10 Carlson Court, Suite 410, Etobicoke, Ontario Canada M9W 6L2 (“Licensee”), on the other hand. Amarin and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
